10 results on '"Hans Gelderblom"'
Search Results
2. A Genetic Polymorphism in
- Author
-
Xiaoyan, Liu, Jesse J, Swen, Meta H M, Diekstra, Epie, Boven, Daniel, Castellano, Hans, Gelderblom, Ron H J, Mathijssen, Sita H, Vermeulen, Egbert, Oosterwijk, Kerstin, Junker, Max, Roessler, Kristin, Alexiusdottir, Asgerdur, Sverrisdottir, Marius T, Radu, Valentin, Ambert, Tim, Eisen, Anne, Warren, Cristina, Rodríguez-Antona, Jesus, García-Donas, Stefan, Böhringer, Karel K M, Koudijs, Lambertus A L M, Kiemeney, Brian I, Rini, and Henk-Jan, Guchelaar
- Subjects
Adult ,Aged, 80 and over ,Male ,Antineoplastic Agents ,Middle Aged ,Prognosis ,Polymorphism, Single Nucleotide ,Survival Analysis ,Treatment Outcome ,Biomarkers, Tumor ,Sunitinib ,Humans ,CTLA-4 Antigen ,Female ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Aged ,Proportional Hazards Models - Published
- 2017
3. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
- Author
-
Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Melanie M. Hagleitner, Remco R. R. Makkinje, Hans Gelderblom, Winette T. A. van der Graaf, H. W. Bart Schreuder, Eveline S. J. M. de Bont, Dunja M.W.M te Loo, Marieke J H Coenen, Hanneke I. Vos, Uta Flucke, Frank N. van Leeuwen, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)
- Subjects
Oncology ,Male ,Cancer Research ,Linkage disequilibrium ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,PROGNOSTIC-FACTORS ,Cytochrome P-450 CYP3A ,Precision Medicine ,INTERGROUP ,Osteosarcoma ,Predictive marker ,Caspase 3 ,ASSOCIATION ,Middle Aged ,Prognosis ,MutS Homolog 2 Protein ,Treatment Outcome ,SURVIVAL ,Female ,Multidrug Resistance-Associated Proteins ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,EXPRESSION ,Adult ,medicine.medical_specialty ,Fas Ligand Protein ,FAS/FASL ,Single-nucleotide polymorphism ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,Polymorphism, Single Nucleotide ,Disease-Free Survival ,Breast cancer ,Internal medicine ,medicine ,BREAST-CANCER ,Humans ,Progression-free survival ,neoplasms ,POLYMORPHISMS ,Genetic Association Studies ,ACUTE LYMPHOBLASTIC-LEUKEMIA ,Aged ,business.industry ,medicine.disease ,Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10] ,Doxorubicin ,Pharmacogenetics ,Immunology ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,Personalized medicine ,LUNG METASTASES ,Cisplatin ,business - Abstract
Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy is the dominant risk factor for poor survival. Pharmacogenetic research can offer possibilities to optimize treatment and improve outcome. We applied a pathway-based approach to evaluate the cumulative effect of genes involved in the metabolism of cisplatin and doxorubicin in relationship to clinical outcome. Experimental Design: We included 126 patients with osteosarcoma. To comprehensively assess common genetic variation in the 54 genes selected, linkage disequilibrium (LD; r2 = 0.8)–based tag-single nucleotide polymorphisms (SNP) strategy was used. A final set of 384 SNPs was typed using Illumina Beadarray platform. SNPs significantly associated with 5-year progression-free survival (PFS) were replicated in another 64 patients with osteosarcoma. Results: We identified five variants in FasL, MSH2, ABCC5, CASP3, and CYP3A4 that were associated with 5-year PFS. Risk stratification based on the combined effects of the risk alleles showed a significant improvement of 5-year PFS. Patients that carried no or only one risk allele had a 5-year PFS of 100% compared with a 5-year PFS of 84.4% for carriers of two or three risk alleles, 66.7% PFS if a patient carried four to five alleles, and a 5-year PFS of 41.8% for patients with >5 risk alleles (P < 0.001). Conclusions: We identified several genes that showed association with PFS in patients with osteosarcoma. These pharmacogenetic risk factors might be useful to predict treatment outcome and to stratify patients immediately after diagnosis and offer the possibility to improve treatment and outcome. Clin Cancer Res; 21(15); 3436–41. ©2015 AACR.
- Published
- 2014
4. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma
- Author
-
Massimo Serra, Arjan C. Lankester, M.W. Schilham, Susy J Santos, Karoly Szuhai, Hans Gelderblom, Jens H.W. Pahl, Pancras C.W. Hogendoorn, S. Eriaty N. Ruslan, Emilie P. Buddingh, and R. Maarten Egeler
- Subjects
musculoskeletal diseases ,Adult ,Antigens, Differentiation, T-Lymphocyte ,Male ,Cancer Research ,Adolescent ,medicine.medical_treatment ,Cetuximab ,Antineoplastic Agents ,Bone Neoplasms ,Sarcoma, Ewing ,Biology ,Antibodies, Monoclonal, Humanized ,Interleukin 21 ,Antigen ,Antigens, CD ,medicine ,Tumor Cells, Cultured ,Humans ,Lectins, C-Type ,Child ,neoplasms ,Antibody-dependent cell-mediated cytotoxicity ,Osteosarcoma ,Antibody-Dependent Cell Cytotoxicity ,Antibodies, Monoclonal ,Immunotherapy ,Middle Aged ,medicine.disease ,Coculture Techniques ,ErbB Receptors ,Killer Cells, Natural ,Oncology ,Immunology ,Monoclonal ,Interleukin 12 ,Leukocytes, Mononuclear ,Female ,Sarcoma ,Drug Screening Assays, Antitumor - Abstract
Purpose: Osteosarcoma and Ewing's sarcoma are the most common bone tumors in children and adolescents. Despite intensive chemotherapy, patients with advanced disease have a poor prognosis, illustrating the need for alternative therapies. Sarcoma cells are susceptible to the cytolytic activity of resting natural killer (NK) cells which can be improved by interleukin (IL)-15 stimulation. In this study, we explored whether the cytolytic function of resting NK cells can be augmented and specifically directed toward sarcoma cells by antibody-dependent cellular cytotoxicity (ADCC). Experimental Design: Epidermal growth factor receptor (EGFR) expression was examined on osteosarcoma and Ewing's sarcoma cell lines by flow cytometry and in osteosarcoma biopsy and resection specimens by immunohistochemistry. Cetuximab-mediated ADCC by NK cells from osteosarcoma patients and healthy controls was measured with 4-hour 51Cr release assays. Results: EGFR surface expression was shown on chemotherapy-sensitive and chemotherapy-resistant osteosarcoma cells (12/12), most primary osteosarcoma cultures (4/5), and few Ewing's sarcoma cell lines (2/7). In the presence of cetuximab, the cytolytic activity of resting NK cells against all EGFR-expressing sarcoma cells was substantially increased and comparable with that of IL-15–activated NK cells. Surface EGFR expression on primary osteosarcoma cultures correlated with EGFR expression in the original tumor. The cytolytic activity of osteosarcoma patient-derived NK cells against autologous tumor cells was as efficient as that of NK cells from healthy donors. Conclusion: Our data show that the cytolytic potential of resting NK cells can be potentiated and directed toward osteosarcoma cells with cetuximab. Therefore, cetuximab-mediated immunotherapy may be considered a novel treatment modality in the management of advanced osteosarcoma. Clin Cancer Res; 18(2); 432–41. ©2011 AACR.
- Published
- 2011
5. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
- Author
-
Maria Debiec-Rychter, Jaap Verweij, Nielka P. van Erp, Henk-Jan Guchelaar, Allan T. van Oosterom, Martine Van Glabbeke, Jean-Yves Blay, Bin Peng, Hans Gelderblom, and Ian Judson
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Anemia ,Antineoplastic Agents ,Bone Neoplasms ,Soft Tissue Neoplasms ,Pharmacology ,Gastroenterology ,Piperazines ,Pharmacokinetics ,Internal medicine ,Medicine ,Humans ,Aged ,Retrospective Studies ,CYP3A4 ,GiST ,business.industry ,Smoking ,CYP1A2 ,Cancer ,Imatinib ,Sarcoma ,Middle Aged ,medicine.disease ,Pyrimidines ,Oncology ,Benzamides ,Imatinib Mesylate ,Female ,business ,medicine.drug - Abstract
Purpose: Smoking is a potent inducer of cytochrome P450 (CYP) 1A2 and may affect the pharmacokinetics of CYP1A2 metabolized drugs. The effect of smoking on the pharmacokinetics of imatinib, which is metabolized by CYP3A4 and partly by CYP1A2, is unknown. We studied the effect of smoking on imatinib pharmacokinetics, safety, and efficacy. Experimental Design: Imatinib pharmacokinetics, safety, and efficacy was analyzed in 45 patients with gastrointestinal stromal tumors (GIST) or soft-tissue sarcoma included in two European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials, including 15 smokers and 30 nonsmokers. Apparent oral clearance, distribution volume, elimination half-life, and dose-standardized area under the concentration curve (AUC) were assessed in 34 patients using nonlinear mixed-effect modeling. Results: Mean ± SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 ± 5.5 versus 9.2 ± 4.6 L/h (apparent oral clearance), 216.5 ± 114.3 versus 207.0 ± 116.9 L (distribution volume), 16.1 ± 6.0 versus 16.5 ± 6.0 h (elimination half-life), and 133.6 ± 71.0 versus 142.3 ± 84.0 ng h/mL mg area under the concentration curve; P > 0.05. Smokers experienced more grade 2/3 anemia (P = 0.010) and fatigue (P = 0.011) and those with GIST had a significantly shorter overall survival (P = 0.037) and time to progression (P = 0.052). Conclusions: This retrospective study suggests that the pharmacokinetics of imatinib is not affected by smoking. However, smokers have an increased risk of anemia and fatigue. Smokers with GIST have a shorter overall survival and time to progression.
- Published
- 2008
6. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan
- Author
-
Nielka P. van Erp, Sharyn D. Baker, Michelle A. Rudek, Hans Gelderblom, Johan W.R. Nortier, Henk-Jan Guchelaar, Alex Sparreboom, and Ming Zhao
- Subjects
Adult ,Male ,Cancer Research ,Time Factors ,Adolescent ,Glucuronidation ,Antineoplastic Agents ,Pharmacology ,Irinotecan ,Silybum marianum ,Pharmacokinetics ,Cytochrome P-450 Enzyme System ,Neoplasms ,medicine ,Cytochrome P-450 CYP3A ,Humans ,Milk Thistle ,Glucuronosyltransferase ,Aged ,CYP3A4 ,biology ,business.industry ,Plant Extracts ,Carcinoma ,Area under the curve ,Drug Synergism ,Middle Aged ,biology.organism_classification ,Antineoplastic Agents, Phytogenic ,Oncology ,Enzyme inhibitor ,Area Under Curve ,biology.protein ,Camptothecin ,Female ,business ,medicine.drug - Abstract
Purpose: Milk thistle (Silybum marianum) is one of the most commonly used herbal therapies, and its principal constituent silybin significantly inhibits cytochrome P450 isoform 3A4 (CYP3A4) and UDP glucuronosyltransferase isoform 1A1 (UGT1A1) in vitro. Here, we investigated whether milk thistle affects the pharmacokinetics of irinotecan, a substrate for CYP3A4 and UGT1A1, in humans. Experimental Design: Six cancer patients were treated with irinotecan (dose, 125 mg/m2) given as a 90-minute infusion once every week. Four days before the second dose, patients received 200 mg milk thistle, thrice a day, for 14 consecutive days. Pharmacokinetic studies of irinotecan and its metabolites 7-ethyl-10-hydroxycamptothecin (SN-38), 7-ethyl-10-[3,4,5-trihydroxy-pyran-2-carboxylic acid]-camptothecin (SN-38-glucuronide), and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin were done during the first three irinotecan administrations. Results: Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16). The area under the curve ratio of SN-38 and irinotecan was slightly decreased by milk thistle (2.58% versus 2.23% versus 2.17%; P = 0.047), whereas the relative extent of glucuronidation of SN-38 was similar (10.8 versus 13.5 versus 13.1; P = 0.64). Likewise, the area under the curve ratio of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin and irinotecan was unaffected by milk thistle (0.332 versus 0.285 versus 0.337; P = 0.53). The maximum plasma concentrations of silybin ranged between 0.0249 and 0.257 μmol/L. Conclusions: Silybin concentrations after intake of milk thistle are too low to significantly affect the function of CYP3A4 and UGT1A1 in vivo, indicating that milk thistle is unlikely to alter the disposition of anticancer drugs metabolized by these enzymes.
- Published
- 2005
7. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
- Author
-
Hans Gelderblom, Clemens Unger, Dirk Behringer, Seth M. Steinberg, Stephan Mielke, Klaus Mross, and Alex Sparreboom
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Paclitaxel ,Gastroenterology ,chemistry.chemical_compound ,Pharmacokinetics ,Internal medicine ,Neoplasms ,Medicine ,Humans ,Risk factor ,Infusion Pumps ,Aged ,Proportional Hazards Models ,business.industry ,Area under the curve ,Peripheral Nervous System Diseases ,Middle Aged ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Peripheral neuropathy ,Treatment Outcome ,Oncology ,chemistry ,Anesthesia ,Pharmacodynamics ,Relative risk ,Area Under Curve ,Toxicity ,Female ,business - Abstract
Purpose: The shortening of infusion time from 3 to 1 hour decreases the systemic exposure (area under the curve, AUC) of total and unbound paclitaxel but increases the AUC of its vehicle Cremophor EL, whereas the time above total paclitaxel concentrations of 0.05 μmol/L (T>0.05) remains almost constant. As both Cremophor EL and paclitaxel are neurotoxic, we evaluated their pharmacodynamic effects on the development of peripheral neuropathy as the most important nonhematologic toxicity. Experimental Design: Patients with advanced cancer of different origin were randomized to receive a maximum of 12 weekly-given 1- or 3-hour infusions of 100 mg/m2 paclitaxel (Taxol). Twenty-four patients were assessable for both pharmacokinetics and peripheral neuropathy development evaluated by a clinical scoring system including sensory symptoms, strength, tendon reflexes, and vibratory sense. Results: Patients with peripheral neuropathy development (n = 14) received more weeks of therapy (P = 0.056) and showed significantly higher T>0.05 (P = 0.022) and overall systemic drug exposures (weeks of therapy × AUC) for total paclitaxel (P = 0.002) and unbound paclitaxel (P = 0.003) than those without peripheral neuropathy. In Kaplan-Meier analyses, T>0.05 ≥ 10.6 hours (P = 0.023), AUC of total paclitaxel ≥ 4.7 μg/mL × hour (P = 0.047), and AUC of unbound paclitaxel ≥ 0.375 μg/mL × hour (P = 0.095) were identified as being potential factors for peripheral neuropathy development. In a Cox regression analysis, only T>0.05 ≥ 10.6 hours remained as an independent risk factor (relative risk, 18.43; P = 0.036) after adjusting for prior vincamycin (relative risk, 11.28; P = 0.038). Conclusions: From the results obtained in this study, it is concluded that exposure to paclitaxel but not Cremophor EL is associated with peripheral neuropathy development.
- Published
- 2005
8. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel
- Author
-
Hans, Gelderblom, Jaap, Verweij, Desirée M, van Zomeren, Dirk, Buijs, Linda, Ouwens, Kees, Nooter, Gerrit, Stoter, and Alex, Sparreboom
- Subjects
Glycerol ,Mesothelioma ,Ovarian Neoplasms ,Paclitaxel ,Gastrointestinal Diseases ,Biological Availability ,Middle Aged ,Antineoplastic Agents, Phytogenic ,Hematologic Diseases ,Injections, Intravenous ,Ascitic Fluid ,Humans ,Female ,Injections, Intraperitoneal ,Aged - Abstract
It has been hypothesized that the paclitaxel vehicle Cremophor EL (CrEL) is responsible for nonlinear drug disposition by micellar entrapment. To gain further insight into the role of CrEL in taxane pharmacology, we studied the pharmacokinetics of paclitaxel in the presence and absence of CrEL after i.p. and i.v. dosing. Patients received an i.p. tracer dose of [G-(3)H]paclitaxel in ethanol without CrEL (100 microCi diluted further in isotonic saline) on day 1, i.p. paclitaxel formulated in CrEL (Taxol; 125 mg/m(2)) on day 4, an i.v. tracer of [G-(3)H]paclitaxel on day 22, and i.v. Taxol (175 mg/m(2)) on day 24. Four patients (age range, 54-74 years) were studied, and serial plasma samples up to 72 h were obtained and analyzed for total radioactivity, paclitaxel, and CrEL. In the presence of CrEL, i.v. paclitaxel clearance was 10.2 +/- 3.76 liters/h/m(2) (mean +/- SD), consistent with previous findings. The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h). The bioavailability of paclitaxel was 31.4 +/- 5.18%, indicating insignificant systemic concentrations after i.p. treatment. CrEL levels were undetectable after i.p. dosing (0.05 microl/ml), whereas after i.v. dosing, the mean clearance was 159 +/- 58.4 ml/h/m(2), in line with earlier observations. In the absence of CrEL, the bioavailability and systemic concentrations of i.p. paclitaxel were significantly increased. This finding is consistent with the postulated concept that CrEL is largely responsible for the pharmacokinetic advantage for peritoneal cavity exposure to total paclitaxel compared with systemic delivery.
- Published
- 2002
9. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens
- Author
-
Wj, Loos, Hans Gelderblom, Sparreboom A, Verweij J, and Mj, Jonge
- Subjects
Clinical Trials, Phase I as Topic ,Dose-Response Relationship, Drug ,Body Surface Area ,Patient Selection ,Administration, Oral ,Antineoplastic Agents ,Drug Administration Schedule ,Area Under Curve ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Cisplatin ,Topotecan ,Retrospective Studies - Abstract
Anticancer drugs still are dosed based on the body-surface area (BSA) of the individual patient, although the BSA is not the main predictor of the clearance for the majority of drugs. The relevance of BSA-based dosing has not been evaluated for topotecan yet. A retrospective pharmacological analysis was performed of kinetic data from four clinical Phase I studies in which topotecan was administered p.o. as a single agent combined with data from a combination study of topotecan and cisplatin. A strong correlation (r = 0.91) was found between the area under the plasma concentration time curve of the lactone and carboxylate forms of topotecan by plotting 326 data sets obtained from 112 patients receiving oral topotecan at dose levels ranging from 0.15-2.70 mg/m2. The intrapatient variability, studied in 47 patients sampled for 3 or more days, for the apparent lactone clearance, ranged from 7.4-69% (mean, 24 +/- 13%; median, 20%). The interpatient variabilities in the lactone clearance, calculated with the data of all studied patients, expressed in liter/h/m2 and in liter/h were 38% and 42%, respectively. In view of the relatively high inter- and intrapatient variabilities in topotecan clearance, in contrast to a variability of only 12% in the BSA of the studied patients, no advantage of BSA-based dosing was found over fixed dose regimens.
- Published
- 2000
10. Topotecan lacks third space sequestration
- Author
-
Hans Gelderblom, Wj, Loos, Verweij J, Mj, Jonge, and Sparreboom A
- Subjects
Adult ,Male ,Metabolic Clearance Rate ,Vomiting ,Antineoplastic Agents ,Nausea ,Middle Aged ,Ondansetron ,Dexamethasone ,Pleural Effusion ,Area Under Curve ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Ascitic Fluid ,Humans ,Female ,Cisplatin ,Topotecan ,Aged - Abstract
The objective of this study was to determine the influence of pleural and ascitic fluid on the pharmacokinetics of the antitumor camptothecin derivative topotecan. Four patients with histological proof of malignant solid tumor received topotecan (0.45 or 1.5 mg/m2) p.o. on several occasions in both the presence and absence of third space volumes. Serial plasma and pleural or ascitic fluid samples were collected during each dosing and analyzed by high-performance liquid chromatography for both the intact lactone form of topotecan and its ring-opened carboxylate form. The apparent topotecan clearance demonstrated substantial interpatient variability but remained unchanged within the same patient in the presence [110 +/- 55.6 liters/ h/m2 (mean +/- SD of eight courses)] or absence of pleural and ascitic fluid [118 +/- 31.1 liters/h/m2 (mean +/- SD of seven courses)]. Similarly, terminal half-lives and area under the concentration-time curve ratios of lactone:total drug in plasma were similar between courses within each patient. Topotecan penetration into pleural and ascitic fluid demonstrated a mean lag time of 1.61 h (range, 1.37-1.86 h), and ratios with plasma concentration increased with time after dosing in all patients. The mean ratio of third space topotecan total drug area under the concentration-time curve to that in plasma was 0.55 (range, 0.26-0.87). These data indicate that topotecan can be safely administered to patients with pleural effusions or ascites and that there is substantial penetration of topotecan into these third spaces, which may prove beneficial for local antitumor effects.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.